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Intra-ventricular thrombus formation remains 
a serious complication after acute myocardial 
infarction (MI) despite early reperfusion therapy 
with primary percutaneous coronary interven-
tion [1]. Vitamin K antagonists (VKAs) have been 
established as the main anticoagulant treatment. 
Nevertheless, patients treated with VKAs need 
good anticoagulation control for optimum effect, 
avoiding bleeding and ischaemic events. There-
fore, non-vitamin K oral anticoagulants (NOACs) 
emerged as effective drugs as VKAs, and safer but 
the effectiveness for a resolution of pre-existing 
intra-ventricular thrombus has, to date, not been 
analyzed. Herein described, for the first time, is 
a case of acute MI complicated by intra-ventricular 
thrombus with poor anticoagulation control with 
VKAs. It was successfully resolved under rivar-
oxaban 20 mg treatment. 
A 43-year-old smoker male with type 2 diabe-
tes undergoing treatment with metformin and good 
metabolic control was referred to the documented 
Emergency Department due to prolonged chest 
pain. The patient had no personal or family his-
tory of thromboembolic events. Electrocardiogram 
revealed sinus rhythm with ST-segment elevation 
in leads V2–V5 and chest radiography showed 
pulmonary congestion. The patient was diagnosed 
with ST-segment elevation MI complicated and was 
administered a loading dose of aspirin 250 mg and 
600 mg of clopidogrel and underwent emergency 
cardiac catheterization. The coronary angiography 
showed a subtotal occlusion of medium left anterior 
descending coronary artery. Subsequent percuta-
neous coronary intervention was performed by 
placement of 2 drug eluting stents (Absorb 3.5 × 
× 20 mm and 3 × 12 mm). Transthoracic echocar-
diography showed anteroseptal and apical akinesia 
with impaired ejection fraction (EF, 35%) and 
a thrombus in the apex of the left ventricle (Fig. 1). 
Magnetic cardiac resonance imaging (Fig. 1) con-
firmed the presence of two small thrombi in the 
apex. During the admission period, no clotting 
abnormalities were observed and platelet count 
was normal in daily blood tests. The patient was 
discharged receiving dual antiplatelet treatment, 
with aspirin 100 mg and clopidogrel 75 mg and oral 
anticoagulation treatment with acenocoumarol. Af-
ter 2 months of anticoagulation, the patient showed 
only one international normalized ratio (INR) value 
within the therapeutic range (INR 2.0–3.0), with 
time in therapeutic range assessed by Rosendaal 
method of 0% and 12.5% by direct method (Fig. 1). 
Frequent visits to the anticoagulation clinic were 
increased and therapeutic adherence was assessed 
to improve the quality of anticoagulation. Unfor-
tunately, the transthoracic echocardiography con-
firmed the presence of thrombi in apex, even with an 
improvement of systolic function (EF 45%) (Fig. 1). 
Because the patient had high SAMe-TT2R2 score 
that predicts poor anticoagulation control under 
VKA therapy, rivaroxaban 20 mg once a day was 
initiated as anticoagulant therapy, maintaining dual 
antiplatelet therapy with aspirin and clopidogrel. 
After 3 months of anticoagulation with rivaroxaban, 
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a new echocardiography confirmed the resolution 
of left ventricular thrombus. The patient presented 
no major bleeding or thromboembolic events dur-
ing treatment with rivaroxaban after 18 months of 
follow-up.
Presented herein, for the first time, records 
the use of rivaroxaban 20 mg as a treatment of 
ventricular thrombus after MI in a patient with 
poor anticoagulation quality with VKA. Recent 
studies have reported an incidence of left ven-
tricular thrombus from 2.5% to 15%, up to 23.5% 
in anterior MI and embolization of left ventricular 
thrombi has been reported in up to 20% of patients 
[1]. Clinical guidelines recommend anticoagulation 
with VKA in addition to dual platelet when MI com-
plicated by a ventricular thrombus to avoid throm-
boembolic events [2]. Unfortunately, triple therapy 
(dual antiplatelet treatment plus anticoagulation 
treatment) increases bleeding risk by more than 
double than with only dual antiplatelet therapy [3]. 
VKAs have shown to be highly effective for stroke 
prevention but the effectiveness is dependent on 
Figure 1. Evolution of left ventricular thrombus with vitamin K antagonists and with rivaroxaban treatment. Upper 
images: Transthoracic echocardiography revealed a fixed mural thrombus in the apex of the left ventricle after 
2 months with anticoagulation treatment with vitamin K antagonists. Middle images: Cardiac magnetic resonance 
with late gadolinium enhancement imaging. The image on the left shows 4-chamber view with a mural thrombus 
adherent to left ventricular apex. Thrombus was easily identified as a low signal-intensity mass surrounded by high 
signal intensity structures in apex due to hyper-enhanced myocardial scar. The middle image shows short axis view 
with hyper-enhanced myocardial scar at septum and two images of ventricular thrombi. The image on the right shows 
the same with a a 2-chamber view. Bottom images: Transthoracic echocardiography revealed complete thrombus 
resolution after 3 months of anticoagulant therapy with rivaroxaban.
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the quality of anticoagulation control. VKA therapy 
has many shortcomings that include routine moni-
toring to achieve its narrow therapeutic index (INR 
2.0–3.0), bleeding complications, drug interactions 
and a slow onset of action [3, 4]. Therapeutic effect 
with VKAs has a high inter and intra-patient vari-
ability and quality of anticoagulation control is the 
result of a dynamic process with the potential for 
rapid and long term variation within the individual 
patient in relation to compliance or intercurrent 
disease. Time in therapeutic range (TTR) is a rec-
ognized measure of quality of anticoagulation treat-
ment, calculated by Rosendaal or by proportion of 
INR values in range (PINRR). Clinical guidelines 
recommend TTR > 70% to achieve high quality 
of anticoagulation treatment. Patients with poor 
anticoagulation control are at risk of both bleeding 
and ischaemic events. Moreover, during the first 
30 days of VKA treatment, there was a 71% increased 
risk of ischemic stroke when compared with no use 
of any antithrombotic therapy, being highest in the 
first weeks due to INR fluctuations and suboptimal 
TTR in the inception phase. Besides the above, 
there is increasing evidence that VKAs have poor 
capability to resolve large intracardiac thrombi [4]. 
To ensure high quality of anticoagulation control, 
many visits to the anticoagulation clinics and sev-
eral dose adjustments are necessary and practical 
barriers such as long distance or sociodemographic 
characteristics of the patients could affect the ad-
herence to VKA therapy [5]. Another reason may 
be access to a health care system and the routine 
follow-up of patients by specialists/cardiologist in-
volved in the anticoagulation control. Other factors 
that could affect the adherence to anticoagulation 
therapy depend on clinical and demographic char-
acteristics of patients: elderly, fragility, polyphar-
macy and comorbidities such as diabetes, kidney 
or liver disease and intercurrent hospitalizations 
during the oral anticoagulants (OAC) therapy [6]. 
Alternatively, the NOACs have shown at least as 
effective as VKAs for thromboembolism prevention 
with fewer intracranial haemorrhages and less drug 
and food interactions [7], with predictable effects.
In this context, the SAMe-TT2R2 score (sex 
female, age < 60, medical history [more than two 
comorbidities], treatment [drugs for rhythm con-
trol], tobacco use [doubled], race [doubled]) arises 
as a simple clinical score to help clinicians decide 
if a patient is likely to do well (score 0–2) or not 
(≥ 2) with VKA [8, 9]. This score may predict pa-
tients with poor INR control who require additional 
interventions to achieve acceptable anticoagula-
tion control with VKAs or perhaps the best initial 
anticoagulation treatment is direct OAC to avoid 
the thromboembolic risk of INR fluctuations of the 
inception phase of ‘trial of VKA’ [10]. The present 
patient had SAMe-TT2R2 = 4 [age < 60: 1 point, 
diabetes and MI with congestive heart failure: 
both 1 point and a smoking habit: 2 points] so it 
was expected the patient would have poor control 
with VKA. Therefore, in this patient, NOACs seem 
to be more effective, stable and safe alternative 
to VKAs for anticoagulation treatment, although 
the effect on ventricular thrombus of NOACs has 
scarcely been explored.
Rivaroxaban, an oral direct inhibitor of factor Xa, 
has performed at least as effective as VKAs 
in stroke prevention in atrial fibrillation patients 
with a better safety profile due the lower rates 
of intracranial hemorrhage (ROCKET-AF) [11]. 
Indeed, rivaroxaban is effective and safe for the 
prevention of venous thromboembolism after 
major orthopedic surgery [12], in the treatment 
of acute deep-vein thrombosis and pulmonary 
embolism and acute coronary syndromes [13]. 
However, no randomized controlled trials have 
been performed to analyze the role of rivaroxaban 
to resolve large and organized intracardiac thrombi. 
X-TRA (Xarelto–ThRombus Accelerated resolu-
tion) was the first prospective study to investigate 
rivaroxaban treatment over 6 weeks for left atrial 
thrombus resolution in 60 patients with atrial fi-
brillation [14]. In addition, a retrospective registry 
(CLOT-AF) analyzed the thrombus resolution rate 
and rivaroxaban had a rate of 62.5% [15]. Makrides 
et al. [16] explored the effect of rivaroxaban on 
ventricular thrombus but at low dose (15 mg). 
However, no large studies have shown the role of 
rivaroxaban in organized left ventricular thrombi 
resolution with a complete dose (20 mg). Despite 
this, rivaroxaban 20 mg was selected because the 
NOAC has more studies in the resolution of cardiac 
thrombi (clinical cases, X-TRA and CLOT-AF) and 
one daily dose could guarantee better adherence 
in young patients. 
When physicians decide to initiate oral antico-
agulation with VKAs, the quality of anticoagulation 
should be closely controlled while trying to achieve 
high TTR. However, if patients have poor anticoag-
ulation quality (such as in this case report) despite 
clinical interventions to improve TTR,  should be 
changed to NOACs. In this case report, presented 
for the first time, was a new method of management 
of rivaroxaban 20 mg as a safe and effective alterna-
tive to VKAs for ventricular thrombus resolution 
in a patient with poor anticoagulation control with 
VKAs. Thus, triple therapy with NOACs may be 
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a new safe and effective treatment for resolution 
of ventricular thrombus in patients with acute 
coronary syndrome, especially in those patients 
who predict poor control with VKA.
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